Department of Orthopedic Surgery, The First Affiliated Hospital of University of South China, 69 Chuanshan Road, Hengyang, Hunan 421001, China.
Department of Orthopaedics, The First Affiliated Hospital, Guangzhou Medical University/Guangdong key Laboratory of Orthopaedic Technology and Implant Materials, Guangzhou 510120, China.
Biomed Res Int. 2021 May 3;2021:9917060. doi: 10.1155/2021/9917060. eCollection 2021.
Enoyl-CoA hydratase and 3-hydroxyacyl CoA dehydrogenase (EHHADH), a member of the 3-hydroxyacyl-CoA dehydrogenase family, were previously demonstrated to be involved in the tumorigenesis of various cancer types. This study is aimed at determining of the diagnostic and prognostic value of EHHADH in osteosarcoma (OS). The overexpression of EHHADH was found both in OS and also other sarcoma types, and according to the retrospective cohort study, the EHHADH level was related to the overall survival and disease-free survival of the OS patients. Furthermore, knockdown of EHHADH under the influence of EHHADH small interfering RNA significantly suppressed the proliferation ability of the tumor cells. Moreover, EHHADH overexpressed was found in human OS tissues. In summary, the progression of OS could be enhanced by EHHADH, which may be a potential diagnostic and prognostic biomarker for OS patients.
烯酰辅酶 A 水合酶和 3-羟酰基辅酶 A 脱氢酶(EHHADH)是 3-羟酰基辅酶 A 脱氢酶家族的成员,先前已被证明参与了多种癌症类型的肿瘤发生。本研究旨在确定 EHHADH 在骨肉瘤(OS)中的诊断和预后价值。在 OS 和其他肉瘤类型中均发现 EHHADH 的过表达,并且根据回顾性队列研究,EHHADH 水平与 OS 患者的总生存率和无病生存率相关。此外,在 EHHADH 小干扰 RNA 的影响下,EHHADH 的敲低显着抑制了肿瘤细胞的增殖能力。此外,在人骨肉瘤组织中发现 EHHADH 过表达。总之,EHHADH 可增强 OS 的进展,可能是 OS 患者的潜在诊断和预后生物标志物。